LncRNA PCAT6 promotes proliferation, migration, invasion, and epithelial-mesenchymal transition of lung adenocarcinoma cell by targeting miR-545-3p

Yang, Chuyi; Huang, Hongyu; Li, Yongpeng; Zhuo, Ting; Zhu, Lu; Luo, Chenyang; Wu, Yunshan; Qin, Simeng

doi:10.1007/s11033-023-08259-x

Cited by 6 publications

(5 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Exosomal miR-181b-5p and let-7c-5p was found to inhibit the EMT process in BEAS-2B cells by modulating the MAPK signaling pathway, resulting in the enhancement of migratory and invasive ability in BEAS-2B cells (84). Moreover, Yang et al showed that lncRNA PCAT6 significantly repressed the migration, invasion, and EMT of A549 and H1975 cells by increasing EGFR expression via sequestering miR-545-3p (131). Liu et al revealed that circSCN8A suppressed invasion, metastasis, and EMT in NSCLC cell lines.…”

Section: Ncrna In Lc Invasion and Metastasismentioning

confidence: 99%

“…EMT is a biological process of cellular morphological alterations in which epithelial cells obtain mesenchymal characteristics. Recent studies suggest that ncRNA dysregulation endows LC cells with invasive and metastatic characteristics by altering EMT (84,131,132). Exosomal miR-181b-5p and let-7c-5p was found to inhibit the EMT process in BEAS-2B cells by modulating the MAPK signaling pathway, resulting in the enhancement of migratory and invasive ability in BEAS-2B cells (84).…”

Section: Ncrna In Lc Invasion and Metastasismentioning

confidence: 99%

See 1 more Smart Citation

Non-coding RNAs in lung cancer: molecular mechanisms and clinical applications

Liu,

Ding,

Wang

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

Lung cancer (LC) is a heterogeneous disease with high malignant degree, rapid growth, and early metastasis. The clinical outcomes of LC patients are generally poor due to the insufficient elucidation of pathological mechanisms, low efficiency of detection and assessment methods, and lack of individualized therapeutic strategies. Non-coding RNAs (ncRNAs), including microRNA (miRNA), long non-coding RNA (lncRNA), and circular RNA (circRNA), are endogenous regulators that are widely involved in the modulation of almost all aspects of life activities, from organogenesis and aging to immunity and cancer. They commonly play vital roles in various biological processes by regulating gene expression via their interactions with DNA, RNA, or protein. An increasing amount of studies have demonstrated that ncRNAs are closely correlated with the initiation and development of LC. Their dysregulation promotes the progression of LC via distinct mechanisms, such as influencing protein activity, activating oncogenic signaling pathways, or altering specific gene expression. Furthermore, some ncRNAs present certain clinical values as biomarker candidates and therapeutic targets for LC patients. A complete understanding of their mechanisms in LC progression may be highly beneficial to developing ncRNA-based therapeutics for LC patients. This review mainly focuses on the intricate mechanisms of miRNA, lncRNA, and circRNA involved in LC progression and discuss their underlying applications in LC treatment.

show abstract

Section: Ncrna In Lc Invasion and Metastasismentioning

confidence: 99%

Section: Ncrna In Lc Invasion and Metastasismentioning

confidence: 99%

Non-coding RNAs in lung cancer: molecular mechanisms and clinical applications

Liu,

Ding,

Wang

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Yang et al. ( 45 ) found that LncRNA PCAT6 promotes proliferation, migration, invasion, and epithelial-mesenchymal transition of lung adenocarcinoma cells by targeting miR-545-3p. Zhong et al.…”

Section: The Regulation Of Signaling Pathway That Lncrna Participated...mentioning

confidence: 99%

“…Wang et al (44) found that LncRNA FBXL19-AS1 induces tumor growth and metastasis by sponging miR-203a-3p in lung adenocarcinoma. Yang et al (45) found that LncRNA PCAT6 promotes proliferation, migration, invasion, and epithelial-mesenchymal transition of lung adenocarcinoma cells by targeting miR-545-3p. Zhong et al (46) found that LncRNA TTN-AS1 drives the invasion and migration of lung adenocarcinoma cells via modulation of miR-4677-3p/ZEB1 axis.…”

Section: Mirna Signaling Axis 581 Mirna-3pmentioning

confidence: 99%

Differential expression and clinical significance of long non-coding RNAs in the development and progression of lung adenocarcinoma

Wei,

Zhang,

Lin

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

With the development of gene testing technology, we have found many different genes, and lncRNA is one of them. LncRNAs refer to a non-protein coding RNA molecule with a length of more than 200bp, which is one of the focuses of research on human malignant diseases such as LUAD. LncRNAs act as an oncogene or inhibitor to regulate the occurrence and progression of tumors. The differential expression of LncRNAs promotes or inhibits the progression of lung adenocarcinoma by affecting cell proliferation, metastasis, invasion, and apoptosis, thus affecting the prognosis and survival rate of patients. Therefore, LncRNAs can be used as a potential target for diagnosis and treatment of cancer. The early diagnosis of the disease was made through the detection of tumor markers. Because lung adenocarcinoma is not easy to diagnose in the early stage and tumor markers are easy to ignore, LncRNAs play an important role in the diagnosis and treatment of lung adenocarcinoma. The main purpose of this article is to summarize the known effects of LncRNAs on lung adenocarcinoma, the effect of differential expression of LncRNAs on the progression of lung adenocarcinoma, and related signal transduction pathways. And to provide a new idea for the future research of lung adenocarcinoma-related LncRNAs.

show abstract

“…Studies identified the dual role of lncRNAs by interacting various signal pathways in LUAD. Some lncRNAs promoted the progression of LUAD, such as lncRNA PCAT6 by sponging miR-545-3p and lncRNA FOXD2-AS1 by regulating cell cycle ( 18 , 19 ). However, some lncRNAs inhibited the progression of LUAD, such as lncRNA SNHG5 by regulating epithelial-mesenchymal transition and lncRNA HITT by attenuating Rab5-mediated endocytosis ( 20 , 21 ).…”

Section: Introductionmentioning

confidence: 99%

Tumor necrosis factor-related lncRNAs predict prognosis and immunotherapy response for patients with lung adenocarcinoma

Chen¹,

Wu²,

Wang³

et al. 2023

J Thorac Dis

View full text Add to dashboard Cite

Background: Lung adenocarcinoma (LUAD) has become one of the most lethal cancers, for which the recurrence and survival rates remain unfavorable. The tumor necrosis factor (TNF) family is involved in tumorigenesis and tumor progression. Various long non-coding RNAs (lncRNAs) play important roles by mediating the TNF family in cancer. Therefore, this study aimed to construct a TNF-related lncRNA signature to predict prognosis and immunotherapy response in LUAD. Methods:The expression of TNF family members and their related lncRNAs in a total of 500 enrolled LUAD patients was collected from The Cancer Genome Atlas (TCGA). Univariate Cox and the least absolute shrinkage and selection operator (LASSO)-Cox analysis was used to construct a TNF family-related lncRNA prognostic signature. Kaplan-Meier (KM) survival analysis was used to evaluate survival status. The time-dependent area under the receiver operating characteristic (ROC) curve (AUC) values were used to assess the predictive value of the signature to 1-, 2-, and 3-year overall survival (OS). Gene Ontology (GO) functional annotation and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were applied to identify the signature-related biological pathways. Furthermore, tumor immune dysfunction and exclusion (TIDE) analysis was employed to evaluate immunotherapy response.Results: A total of 8 TNF-related lncRNAs significantly associated with OS of LUAD patients were used to construct a TNF family-related lncRNA prognostic signature. According to risk score, these patients were divided into high-and low-risk subgroups. The KM survival analysis indicated that patients in the high-risk group showed significantly less favorable OS than that of low-risk group. The AUC values in predicting 1-, 2-, and 3-year OS were 0.740, 0.738, and 0.758, respectively. Moreover, the GO and KEGG pathway analyses demonstrated that these lncRNAs were closely involved in immune-related signaling pathways. The further TIDE analysis indicated that high-risk patients had a lower TIDE score than that of low-risk patients, indicating that high-risk patients may be appropriate candidates for immunotherapy. Conclusions:For the first time, this study constructed and validated a prognostic predictive signature of LUAD patients based on TNF-related lncRNAs, and the signature showed good performance to predict immunotherapy response. Therefore, this signature may provide new strategies for individualized treatment of LUAD patients.

show abstract

LncRNA PCAT6 promotes proliferation, migration, invasion, and epithelial-mesenchymal transition of lung adenocarcinoma cell by targeting miR-545-3p

Cited by 6 publications

References 36 publications

Non-coding RNAs in lung cancer: molecular mechanisms and clinical applications

Non-coding RNAs in lung cancer: molecular mechanisms and clinical applications

Differential expression and clinical significance of long non-coding RNAs in the development and progression of lung adenocarcinoma

Tumor necrosis factor-related lncRNAs predict prognosis and immunotherapy response for patients with lung adenocarcinoma

Contact Info

Product

Resources

About